中国药师
中國藥師
중국약사
CHINA PHARMACIST
2015年
4期
541-544,554
,共5页
索拉非尼%Eudragit RS100%纳米粒%溶剂-非溶剂法%优化%体外释放
索拉非尼%Eudragit RS100%納米粒%溶劑-非溶劑法%優化%體外釋放
색랍비니%Eudragit RS100%납미립%용제-비용제법%우화%체외석방
Sorafenib%Eudragit RS100%üanoparticles%Solvent-nonsolvent method%Optimization%In vitro release
目的:制备索拉非尼-Eudragit RS 纳米粒( sorafenib-Eudragit RS nanoparticles,S-E üPs),优选制备处方及初步探索其理化性质。方法:溶剂-非溶剂法制备索拉非尼-Eudragit RS纳米粒,采用单因素试验研究溶剂、稳定剂类型、载体比例、有机相水相比例对纳米粒理化性质的影响。通过粒径和Zeta电位、形貌观察、体外释药考察对其进行质量评价。结果:优选处方制备的索拉非尼-Eudragit RS 纳米粒的平均粒径为(86.72±3.71)nm,多相分散系数(PDI)为(0.200±0.032),Zeta 电位为(36.6±0.3)mV,纳米粒呈球形且分布均匀;体外释放符合 Weibull 模型(r=0.9669)。结论:溶剂-非溶剂法适用于索拉非尼-Eudragit RS 纳米粒的制备,所制备的纳米粒粒径较小,分布均匀,形态规则完整,具有明显缓释作用。
目的:製備索拉非尼-Eudragit RS 納米粒( sorafenib-Eudragit RS nanoparticles,S-E üPs),優選製備處方及初步探索其理化性質。方法:溶劑-非溶劑法製備索拉非尼-Eudragit RS納米粒,採用單因素試驗研究溶劑、穩定劑類型、載體比例、有機相水相比例對納米粒理化性質的影響。通過粒徑和Zeta電位、形貌觀察、體外釋藥攷察對其進行質量評價。結果:優選處方製備的索拉非尼-Eudragit RS 納米粒的平均粒徑為(86.72±3.71)nm,多相分散繫數(PDI)為(0.200±0.032),Zeta 電位為(36.6±0.3)mV,納米粒呈毬形且分佈均勻;體外釋放符閤 Weibull 模型(r=0.9669)。結論:溶劑-非溶劑法適用于索拉非尼-Eudragit RS 納米粒的製備,所製備的納米粒粒徑較小,分佈均勻,形態規則完整,具有明顯緩釋作用。
목적:제비색랍비니-Eudragit RS 납미립( sorafenib-Eudragit RS nanoparticles,S-E üPs),우선제비처방급초보탐색기이화성질。방법:용제-비용제법제비색랍비니-Eudragit RS납미립,채용단인소시험연구용제、은정제류형、재체비례、유궤상수상비례대납미립이화성질적영향。통과립경화Zeta전위、형모관찰、체외석약고찰대기진행질량평개。결과:우선처방제비적색랍비니-Eudragit RS 납미립적평균립경위(86.72±3.71)nm,다상분산계수(PDI)위(0.200±0.032),Zeta 전위위(36.6±0.3)mV,납미립정구형차분포균균;체외석방부합 Weibull 모형(r=0.9669)。결론:용제-비용제법괄용우색랍비니-Eudragit RS 납미립적제비,소제비적납미립립경교소,분포균균,형태규칙완정,구유명현완석작용。
Objective:To prepare and optimize sorafenib-Eudragit RS nanoparticles( S-E üPs)and investigate the physicochemi-cal properties. Methods:S-E üPs were prepared by a solvent-nonsolvent method. Single factor experiments were used to research the effect of solvent,stabilizer type,carrier ratio and the proportions of water phase and organic phase on the physicochemical properties of S-E üPs. S-E üPs were evaluated by the particle size,zeta potential and morphology,and the in vitro drug release of S-E üPs was studied using dialysis technology. Results:The mean size was(86. 72 ± 3. 71)nm,the PDI and zeta potential was(0. 20 ± 0. 032)and (36. 6 ± 0. 3)mV,respectively,S-E üPs showed spherical shape with uniform distribution. The drug release in vitro was accorded with a Weibull equation. Conclusion:The solvent-nonsolvent method is appropriate for the preparation of S-E üPs. The nanoparticles have small particle size,uniform distribution,regular morphology and significant sustained-release property.